Paecilomyces lilacinus, also known as Purpureocillium lilacinum, is a non-dermatophyte mold found in the soil and used as nematocide for crops. P. lilacinus can cause rare opportunistic infections in humans ranging from endocarditis, keratitis, to onychomycosis with significant resistance to conventional antifungals. There are only two cases of onychomycosis caused by P. lilacinus reported in the literature and none that were successfully treated. Here we present a case of successfully treated onychomycosis caused by P. lilacinus with efinaconazole and tavaborole in a patient who had failed treatment with oral fluconazole, itraconazole, terbinafine, and topical ciclopirox and naftifine.

Keywords:
Efinaconazole, Tavaborole, Treatment, Non-dermatophyte, Paecilomyces lilacinus, Purpureocillium lilacinum, Onychomycosis
1.
Luangsa-Ard J, Houbraken J, van Doorn T, Hong SB, Borman AM, Hywel-Jones NL, Samson RA: Purpureocillium, a new genus for the medically important Paecilomyces lilacinus. FEMS Microbiol Lett 2011;321:141-149.
2.
Pastor FJ, Guarro J: Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2006;12:948-960.
3.
Fletcher CL, Hay RJ, Midgley G, Moore M: Onychomycosis caused by infection with Paecilomyces lilacinus. Br J Dermatol 1998;139:1133-1135.
4.
Innocenti P, Pagani E, Vigl D, Höpfl R, Huemer HP, Larcher C: Persisting Paecilomyces lilacinus nail infection following pregnancy. Mycoses 2011;54:e880-e882.
5.
Hall VC, Goyal S, Davis MD, Walsh JS: Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus: report of three cases and review of the literature. Int J Dermatol 2004;43:648-653.
6.
Iwen PC, Hinrichs SH, Rupp ME: Utilization of the internal transcribed spacer regions as molecular targets to detect and identify human fungal pathogens (review). Med Mycol 2002;40:87-109.
7.
Castelli MV, Alastruey-Izquierdo A, Cuesta I, Monzon A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M: Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother 2008;52:2926-2928.
8.
Aguilar C, Pujol I, Sala J, Guarro J: Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother 1998;42:1601-1604.
9.
Del Rosso JQ: The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol 2014;7:10-18.
10.
Lipner SR, Scher RK: Efinaconazole in the treatment of onychomycosis. Infect Drug Resist 2015;8:163-172.
11.
Elewski BE, Tosti A: Tavaborole for the treatment of onychomycosis. Expert Opin Pharmacother 2014;15:1439-1448.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.